Loading…
Bioventus amended its agreement to acquire CartiHeal, reducing the closing payment to $50 million and deferring $215 million into tranches, with the acquisition expected to close by end of July 2022.
Bioventus Inc. exercised its call option to acquire CartiHeal Ltd. for approximately $315 million, with an additional $135 million contingent on sales milestones, following FDA approval of CartiHeal's Agili-C implant.
Bioventus has made a $50 million escrow payment signaling its intent to acquire Israeli medtech company CartiHeal for approximately $500 million, pending FDA approval of CartiHeal's Agili-C implant.